Neuroendocrine Tumor Treatment

Global Neuroendocrine Tumor Treatment Market to Reach US$4.4 Billion by 2030

The global market for Neuroendocrine Tumor Treatment estimated at US$3.3 Billion in the year 2024, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$908.4 Million While China is Forecast to Grow at 7.2% CAGR

The Neuroendocrine Tumor Treatment market in the U.S. is estimated at US$908.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$850.2 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Neuroendocrine Tumor Treatment Market – Key Trends & Drivers Summarized

Why Are Neuroendocrine Tumors Requiring More Specialized Therapeutic Approaches?

Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies that originate from neuroendocrine cells, most commonly found in the gastrointestinal tract, lungs, and pancreas. While historically considered rare and slow-growing, NETs have seen a rise in incidence due to improved diagnostic techniques and heightened clinical awareness. Despite their often indolent nature, NETs present unique challenges due to their variable behavior, potential for hormone secretion, and late-stage detection. The clinical management of NETs has therefore shifted toward more individualized, multidisciplinary strategies that combine tumor control with symptom management.

Because NETs can range from well-differentiated, non-functioning tumors to highly aggressive and hormonally active neoplasms, treatment requires a delicate balance between cytoreduction and hormonal control. Traditional cytotoxic chemotherapy has limited effectiveness in many NET subtypes, prompting a move toward targeted therapies, peptide receptor radionuclide therapy (PRRT), and biotherapy. These evolving strategies aim not just to extend progression-free survival but also to improve quality of life, especially for patients with functional NETs causing symptoms like carcinoid syndrome.

How Are Targeted Therapies and PRRT Shaping Modern Treatment Paradigms?

Targeted therapies have become a cornerstone in the treatment of advanced or metastatic NETs, offering more precise and tolerable options compared to traditional chemotherapy. Agents such as everolimus (an mTOR inhibitor) and sunitinib (a tyrosine kinase inhibitor) have demonstrated efficacy in prolonging progression-free survival in pancreatic and non-pancreatic NETs. These therapies interfere with molecular pathways involved in tumor proliferation and angiogenesis, allowing for more tailored treatment based on tumor biology.

Peptide receptor radionuclide therapy (PRRT), particularly with radiolabeled somatostatin analogs like Lutetium-177-DOTATATE, has emerged as a highly effective option for patients with somatostatin receptor-positive NETs. PRRT delivers targeted radiation to tumor cells, minimizing damage to surrounding tissues and providing durable disease control. Its success has driven further research into newer radionuclide agents and combination regimens. Additionally, somatostatin analogs such as octreotide and lanreotide remain vital for symptom control and tumor stabilization in patients with functional tumors. These advancements underscore a broader trend toward biologically guided, non-invasive therapies that improve patient outcomes with fewer adverse effects.

Which Diagnostic and Monitoring Strategies Are Enhancing Treatment Precision?

Advances in diagnostic imaging and biomarker identification are enabling more accurate staging and monitoring of neuroendocrine tumors. Functional imaging techniques such as Gallium-68 DOTATATE PET/CT have become standard for assessing somatostatin receptor expression, which not only aids diagnosis but also determines eligibility for PRRT. This form of precision imaging provides better resolution and sensitivity than traditional scans, facilitating earlier intervention and more targeted treatment planning.

Additionally, circulating biomarkers such as chromogranin A (CgA) and neuron-specific enolase (NSE) are being complemented by genomic profiling and circulating tumor DNA (ctDNA) assessments. These tools provide insights into tumor grade, proliferation index (Ki-67), and potential resistance mechanisms, enabling clinicians to adapt therapy dynamically. As treatment regimens become more complex, ongoing monitoring through imaging and molecular diagnostics ensures that therapy remains aligned with disease progression and evolving tumor biology. This precision-driven approach is reshaping the management of NETs and opening the door to more effective long-term control.

What Factors Are Driving Growth in the Neuroendocrine Tumor Treatment Market?

The growth in the neuroendocrine tumor treatment market is driven by several interlinked factors related to clinical innovation, rising disease awareness, and broader adoption of targeted care pathways. A key driver is the increasing incidence and detection of NETs, supported by more sophisticated imaging techniques and improved diagnostic algorithms. As clinicians become more attuned to the unique presentation of NETs, especially in early-stage patients, diagnosis rates are climbing, expanding the treatable patient pool.

End-use expansion across tertiary care hospitals, cancer specialty centers, and academic medical institutions is supporting the wider adoption of advanced therapies like PRRT, targeted biologics, and image-guided interventions. Reimbursement support for high-cost treatments and favorable regulatory approvals are also facilitating patient access to novel therapies. Additionally, growing investment in clinical trials focused on immunotherapy, radionuclide combinations, and new somatostatin receptor analogs is enhancing the market’s innovation pipeline.

Support from patient advocacy groups and increased inclusion of NETs in cancer awareness campaigns are driving both public and clinical recognition of the disease. As multi-modal treatment strategies become the norm—incorporating targeted therapy, radiopharmaceuticals, hormone suppression, and surveillance—the demand for specialized, high-precision therapeutics is poised to grow steadily. Collectively, these trends are fostering sustained advancement and commercial expansion within the neuroendocrine tumor treatment landscape.

SCOPE OF STUDY:

The report analyzes the Neuroendocrine Tumor Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Somatostatin Analogs, Chemotherapy, Targeted Therapy, Immunotherapy, Other Drug Classes); Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Other Indications); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Advanced Accelerator Applications
• AVEO Oncology
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Camurus AB
• Delcath Systems
• Eli Lilly and Company
• Exelixis, Inc.
• Hutchison MediPharma
• Ipsen
• ITM Isotopen Technologien München AG
• Jubilant Pharmova Limited
• Lantheus Holdings, Inc.
• Novartis AG
• Orano Med
• Pfizer Inc.
• Progenics Pharmaceuticals
• Radiomedix, Inc.
• RayzeBio, Inc.
• Sanofi

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more